Cinatl J, Cinatl J, Rabenau H, Gümbel H O, Kornhuber B, Doerr H W
Department of Medical Virology, Universitätsklinikum, J.W. Goethe-Universität, Frankfurt a. M., Germany.
Antiviral Res. 1994 Sep;25(1):73-7. doi: 10.1016/0166-3542(94)90095-7.
Desferrioxamine (DFO) is commonly used in therapy as a chelator of ferric ion in disorders of iron overload. We found that DFO inhibits human cytomegalovirus (HCMV) replication in infected cultures of human foreskin fibroblasts (HFF) at concentrations that have been achieved in humans with no significant adverse effects. The concentrations of DFO required for 50 and 90% reduction in the production of a HCMV-late antigen ranged for several HCMV strains from 3.1 to 4.9 microM and from 14.2 to 17.3 microM, respectively. DFO concentration of 60 microM had no significant effect on the viability of HFF cells. Inhibitory effects of DFO on HCMV replication were completely prevented by co-incubation with stoichiometric amounts of Fe3+.
去铁胺(DFO)作为铁过载疾病中铁离子的螯合剂,常用于治疗。我们发现,在人体已达到的浓度且无明显不良反应的情况下,DFO可抑制人包皮成纤维细胞(HFF)感染培养物中的人巨细胞病毒(HCMV)复制。对于几种HCMV毒株,使HCMV晚期抗原产生减少50%和90%所需的DFO浓度分别为3.1至4.9微摩尔/升和14.2至17.3微摩尔/升。60微摩尔/升的DFO浓度对HFF细胞活力无显著影响。与化学计量的Fe3+共同孵育可完全消除DFO对HCMV复制的抑制作用。